In Brief: Technical Chemicals and Products, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Technical Chemicals and Products, Inc.: Acquires remaining 20% of Health-Mark Diagnostics, manufacturer of the recently launched HealthCheck line of over-the-counter test kits. The deal makes HMD a wholly owned subsidiary of TCPI, which says it plans to consolidate HMD's Mountain Lakes, New Jersey-based operations into TCPI's facility in Pompano Beach, Florida. HealthCheck products cleared by FDA include kits for pregnancy and ovulation; vision screening and skin growth monitoring. Tests for urine nitrate (urinary tract infections), urine glucose (diabetes), and urine protein (kidney/bladder disorders) "are in the final phase of FDA review and are expected to be released shortly," the firm says...
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip